Prof. dr. Stefaan De Smedt
Laboratory of General Biochemistry & Physical Pharmacy
Harelbekestraat 72, B-9000 Ghent, Belgium
Phone: +32 9 264 80 76
Fax: +32 9 264 81 89
Stefaan De Smedt (°1967 studied pharmacy at Ghent University and received his MS degree in pharmaceutical sciences in 1990. As a scholar of the Belgian Institute for the Encouragement of Scientific Research in Industry and Agriculture, he enrolled in a Ph.D. program at Ghent University, under the direction of Prof. J. Demeester. He studied rheology at the Catholic University of Leuven. He received the Scott Blair Biorheology Award in 1993-1995 for his work on the structural characterization of hyaluronan solutions. To study diffusion phenomena in polymer solutions, he collaborated with Prof. Y. Engelborghs at the Laboratory of Biomolecular Dynamics of the Catholic University of Leuven. In 1995, he joined the pharmaceutical development group of Janssen Research Foundation. Since 1997 he has been a post-doctoral fellow of F.W.O.–Vlaanderen at the Laboratory of General Biochemistry & Physical Pharmacy of Ghent University and at the Department of Pharmaceutics of the University of Utrecht. In October 1999 he became Professor in Physical Pharmacy & Biopharmacy at Ghent University. Since 2004 Professor De Smedt has been Assistant Editor for Europe of the Journal of Controlled Release. He is a representative of the members of Eufeps (European Federation for Pharmaceutical Sciences) in the Eufeps Council and takes the chair for the Eufeps Committee for Training and Education. Professor De Smedt is a member of the Belgian and Dutch Society for Pharmaceutical Sciences, Controlled Release Society, the Biophysical Society, the American Association of Pharmaceutical Scientists and the European Society for Gene Therapy. Stefaan De Smedt is one of the scientific founders of Memobead Technologies, a spin-off from Ghent University focussed on the development of encoded microcarriers for drug screening and diagnostics.
This technology platform is currently under further development by Biocartis, a Swiss company engaged in the development of diagnostic solutions for commercial point of care applications